TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients

Table 1 Circulating tumor cells (CTCs) harboring the TP53 exon 4 mutation and wild-type allele

Patient ID	TP53 mutation
	Isolated CTCs	Isolated white blood cells (WBCs)
TRF001321	Single CTC (4994): TP53 R110 delC fs*13	Single WBC (5022): no mutation
	Single CTC (2597): no mutation	Single WBC (4940): no mutation
	Single CTC (2319): no mutation	Single WBC (4907): no mutation
	Single CTC (2310): no mutation	Single WBC (33): no mutation
	Single CTC (50): TP53 R110 delG fs*13
	Single CTC (2424): no mutation
	Pool of 14 CTCs: TP53 R110 delC fs*13
TRF000155	Single CTC (925): TP53 R110 delC fs*13	Single WBC (491): no mutation
	Cluster of 6 CTCs (1168): TP53 R110 delC fs*13	Single WBC (426): no mutation
	Single CTC (475): TP53 R110 delCfs*13	Single WBC (337): no mutation
	Cluster of 2 CTCs (476): TP53 R110 delC fs*13	Single WBC (77): no mutation
	Cluster of 3 CTCs (346): TP53 R110 delC fs*13	Single WBC (261): no mutation
	Cluster of 3 CTCs (300): TP53 R110 delC fs*13	Single WBC (289): no mutation
	Single CTC (1944): TP53 R110 delC fs*13	Single WBC (1775): no mutation
	Single CTC (1645): no mutation	Single WBC (1564): no mutation
	Single CTC (806): no mutation	Single WBC (662): no mutation
	Cluster of 2 CTCs (209): TP53 R110 delC fs*13
	Cluster of 3 CTCs (816): no mutation

CTCs and WBCs were isolated from two patients with metastatic triple-negative breast cancer. The cells shown in Figures 3 and 4 were studied; cell ids are indicated (in parenthesis). As control for the wild-type TP53 allele, four, and nine, WBCs from patients TRF001321 and TRF000155, respectively, were isolated and TP53 were sequenced; del, deletion; fs*13, frameshift mutation that creates a premature stop codon 13 aminoacids downstream.

ISSN: 1465-542X